Literature DB >> 28714420

Evaluation of Temporal Changes in Urine-based Metabolomic and Kidney Injury Markers to Detect Compound Induced Acute Kidney Tubular Toxicity in Beagle Dogs.

M P Wagoner1, Y Yang2, J E McDuffie3, M Klapczynski2, W Buck2, L Cheatham4, D Eisinger5, F Sace6, K M Lynch2, M Sonee3, J-Y Ma3, Y Chen3, K Marshall3, M Damour3, L Stephen3, Y P Dragan5, J Fikes7, S Snook3, L B Kinter8.   

Abstract

Urinary protein biomarkers and metabolomic markers have been leveraged to detect acute Drug Induced Kidney Injury (DIKI) in rats; however, the utility of these indicators to enable early detection of DIKI in canine models has not been well documented. Therefore, we evaluated temporal changes in biomarkers and metabolites in urine from male and female beagle dogs. Gentamicin- induced kidney lesions in male dogs were characterized by moderate to severe tubular epithelial cell degeneration/necrosis, epithelial cell regeneration and dilation; and a unique urinebased metabolomic fingerprint. These metabolite changes included time and treatment-dependent increases in lactate, taurine, glucose, lactate, alanine, and citrate as well as 9 other known metabolites. As early as 3 days post dose, gentamicin induced increases in urinary albumin, clusterin, neutrophil gelatinase associated protein (NGAL) and total protein concentrations. Urinary albumin, clusterin, and NGAL showed earlier and more robust elevations than traditional kidney safety biomarkers, blood urea nitrogen and serum creatinine. Elevations in urinary kidney injury molecule 1 (KIM-1) were less reliable for detection of gentamicin nephrotoxicity in dogs based on values generated utilizing multiple first-generation, canine-specific KIM-1 immunoassays. The metabolic fingerprint was further evaluated in male and female dogs that received Compound A which induced slightly reversible renal tubular alterations characterized as degeneration/necrosis and concurrent significant increases in urinary taurine amongst other markers. These data support further investigations to demonstrate the value of urinary metabolites, albumin, clusterin, NGAL and taurine as promising markers to enable early detection of DIKI in dogs. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Acute Drug Induced Kidney Injury (DIKI); EMA.; Metabolomics; NGAL; Protein biomarkers; Rats

Mesh:

Substances:

Year:  2017        PMID: 28714420     DOI: 10.2174/1568026617666170713172331

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  5 in total

1.  Validation of a commercial magnetic bead-based multiplex assay for 5 novel biomarkers of acute kidney injury in canine serum.

Authors:  Jennifer Davis; Anthea L Raisis; David W Miller; Gabriele Rossi
Journal:  J Vet Diagn Invest       Date:  2020-07-05       Impact factor: 1.279

2.  Proteomic Analysis of Urine from California Sea Lions ( Zalophus californianus): A Resource for Urinary Biomarker Discovery.

Authors:  Benjamin A Neely; Katherine C Prager; Alison M Bland; Christine Fontaine; Frances M Gulland; Michael G Janech
Journal:  J Proteome Res       Date:  2018-08-28       Impact factor: 4.466

Review 3.  Canine metabolomics advances.

Authors:  Graciela Carlos; Francisco Paulo Dos Santos; Pedro Eduardo Fröehlich
Journal:  Metabolomics       Date:  2020-01-18       Impact factor: 4.290

Review 4.  Renal biomarkers in cats: A review of the current status in chronic kidney disease.

Authors:  Thirawut Kongtasai; Dominique Paepe; Evelyne Meyer; Femke Mortier; Sofie Marynissen; Lisa Stammeleer; Pieter Defauw; Sylvie Daminet
Journal:  J Vet Intern Med       Date:  2022-02-26       Impact factor: 3.333

5.  Kidney Injury Molecule-1 Is Upregulated in Renal Lipotoxicity and Mediates Palmitate-Induced Tubular Cell Injury and Inflammatory Response.

Authors:  Xueying Zhao; Xiaoming Chen; Yuanyuan Zhang; Jasmine George; Alyssa Cobbs; Guoshen Wang; Lingyun Li; Nerimiah Emmett
Journal:  Int J Mol Sci       Date:  2019-07-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.